IntelGenx Technologies Corp.

IGXT

US45822R1014

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 20:57:54 16/05/2024 BST			5-day change	1st Jan Change
0.167 ^USD	-3.75%		0.00%	+20.93%

05-28	IntelGenx Brief: Says Obtained Court-Approval of a Sale and Investment Solicitation Process; Had Recently Initiated Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives	MT
05-28	ATAI Life Sciences AG entered into an agreement of purchase and sale to acquire the Assets of IntelGenx Technologies Corp..	CI

IntelGenx Corp. Appoints Mark Nawacki as a Special Advisor to the Executive Team

January 29, 2016 at 06:46 am

IntelGenx Corp. announced that it has further strengthened its organization with the engagement of Mr. Mark Nawacki as a Special Advisor to the Executive team. Mr. Nawacki is currently the President and CEO of Searchlight Pharma Inc.

Latest news about IntelGenx Technologies Corp.

IntelGenx Brief: Says Obtained Court-Approval of a Sale and Investment Solicitation Process; Had Recently Initiated Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives	05-28	MT
ATAI Life Sciences AG entered into an agreement of purchase and sale to acquire the Assets of IntelGenx Technologies Corp..	05-27	CI
IntelGenx Begins Restructuring Proceedings Under CCAA to Implement Review of Strategic Alternatives	05-21	MT
IntelGenx Brief: Initiating Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives	05-17	MT
IntelGenx Technologies Corp. Announces Board Resignations	05-17	CI
IntelGenx Technologies Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives	05-16	CI
IntelGenx Technologies Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
Intelgenx Announces First Parkinson?S Disease Patients Dosed with Montelukast Versafilm® in Phase 2 ?Montpark? Clinical Trial	04-08	CI
IntelGenx Updates Status of Buprenorphine Buccal Film ANDA	04-05	MT
IntelGenx Corp. Updates Status of Buprenorphine Buccal Film ANDA	04-05	CI
IntelGenx Technologies Narrows Q4 Loss, Revenue Rises	03-21	MT
Transcript : IntelGenx Technologies Corp., Q4 2023 Earnings Call, Mar 21, 2024	03-21
IntelGenx Technologies Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	03-21	CI
IntelGenx Subsidiary Signs Third Amended, Restated Loan Agreement With atai Life Sciences	03-11	MT
IntelGenx Brief: Entering Into a Third Amended and Restated Loan Agreement With atai Life Sciences	03-11	MT
IntelGenx Technologies Corp. announced that it expects to receive $2 million in funding	03-07	CI
IntelGenx Brief: Launching Regulation A Offering of Up to 2 Million shares In Series A Convertible Cumulative Preferred Stock, Par Value $0.00001 Per Share, at an Offering Price of $10.00 Each, For a Max Offering amount of $20 Million	02-20	MT
IntelGenx Technologies Corp. announced that it expects to receive $20 million in funding	02-13	CI
IntelGenx Technologies Corp. Announces Positive Results from Proof-Of-Concept Study to Assess the Palatability, Owner-Perceived Acceptability, and Ease of Repeated Administration of Intelgenx?s VetaFilm® Platform in Healthy Dogs and Cats	02-05	CI
IntelGenx, Covenant Animal Health Partners Unit Sign Development, License Pacts for VetaFilm	12-18	MT
IntelGenx Corp. Announces New Animal Health Partnership; Enters into Development and License Agreements for VetaFilm	12-18	CI
IntelGenx Brief: Announcing New Animal Health Partnership; Enters into Development and License Agreements for VetaFilm	12-18	MT
IntelGenx Technologies Corp. announced that it has received CAD 1.01451 million in funding from ATAI Life Sciences AG	12-04	CI
IntelGenx Technologies Corp. Announces Changes to its Board of Directors	12-04	CI
IntelGenx Announcing Shareholder Approval of Financing Transactions	11-28	MT

Chart IntelGenx Technologies Corp.

Duration

Period

More charts

Company Profile

IntelGenx Technologies Corp. is a Canada-based drug delivery company. The Company provides single-site, end-to-end contract development and manufacturing services of oral thin film and transdermal drug products for the pharmaceutical and animal health markets, spanning the entire drug development and commercial product cycle. The Companyâs film technologies, including VersaFilm, DisinteQ, VetaFilm and transdermal VevaDerm, allows for pharmaceutical products that address unmet medical needs. It provides comprehensive pharmaceuticals services to pharmaceutical partners, including research and development (R&D), analytical method development, clinical monitoring, IP and regulatory services. Its manufacturing facility offers full service by providing lab-scale to pilot- and commercial-scale production. Its product portfolio includes Migraine (Rizatriptan), Erectile Dysfunction (Tadalafil), Schizophrenia (Lozapine), Neurodegenerative, Opioid Dependence (Buprenorphine / Naloxone) and others.

Sector

Pharmaceuticals

Calendar

07/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
INTELGENX TECHNOLOGIES CORP.	+20.93%	29.17M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+17.19%	42.25B
OTSUKA HOLDINGS CO., LTD.	+15.26%	21.27B
SANDOZ GROUP AG	+19.33%	15.23B
CIPLA LIMITED	+19.08%	14.36B
ZYDUS LIFESCIENCES LIMITED	+50.38%	12.74B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-12.22%	6.61B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+14.28%	5.66B